Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017.

"Declarations Conflict of interestM.R. received travel support from Almirall Hermal, outside the submitted work. U.L. received grants from MSD (Squamous cell carcinoma, Melanoma adjuvant), honoraria as a speaker for MSD, Novartis, Sun Pharma, Sanofi, Roche, Almirall Hermal and travel support from Sun Pharma, Pierre Fabre, outside the submitted work. T.A. received institutional grants from SkylineDx, Neracare, Novartis, Sanofi and consulting fees from Novartis, Neracare, BMS, CeCaVa and Chemosat, outside the submitted work. C.G. received Consulting fees from CeCaVa, MSD, NeraCare and Philogen. A.F. served as a consultant to Novartis, MSD, BMS, Pierre-Fabre and Immunocore; received travel support from Novartis, BMS, Pierre-Fabre, and received speaker fees from Novartis, BMS and MSD and reports institutional research grants from BMS Stiftung Immunonkologie, outside the submitted work. The other authors declare that they have no conflicts of interest. Ethical approvalThis retrospective analysis adhered to the guidelines of the local ethical committee of the University Hospital Tübingen and followed the general recommendations outlined in the Declaration of Helsinki. Consent to participate and publishAll patients included in this registry provided written informed consent for documentation of their clinical data in the central melanoma registry for research purposes and publications. Conflict of interest M.R. received travel support from Almirall Hermal, outside the submitted work. U.L. received grants from MSD (Squamous cell carcinoma, Melanoma adjuvant), honoraria as a speaker for MSD, Novartis, Sun Pharma, Sanofi, Roche, Almirall Hermal and travel support from Sun Pharma, Pierre Fabre, outside the submitted work. T.A. received institutional grants from SkylineDx, Neracare, Novartis, Sanofi and consulting fees from Novartis, Neracare, BMS, CeCaVa and Chemosat, outside the submitted work. C.G. received Consulting fees from CeCaVa, MSD, NeraCare and Philogen. A.F. served as a consultant to Novartis, MSD, BMS, Pierre-Fabre and Immunocore; received travel support from Novartis, BMS, Pierre-Fabre, and received speaker fees from Novartis, BMS and MSD and reports institutional research grants from BMS Stiftung Immunonkologie, outside the submitted work. The other authors declare that they have no conflicts of interest."

"Funding Open Access funding enabled and organized by Projekt DEAL. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors."